D. Nosov

发表

Efficacy of tivozanib treatment after sorafenib in patients with advanced renal cell carcinoma: crossover of a phase 3 study

R. Motzer, C. Sternberg, P. Tomczak, 2018, European journal of cancer.

Nilotinib vs imatinib as first-line therapy for patients with unresectable or metastatic gastrointestinal stromal tumours: randomised phase 3 trial results and subgroup analysis of molecular subtypes

A. Cesne, Yoon-Koo Kang, P. Rutkowski, 2015 .

Tivozanib versus sorafenib as initial targeted therapy for patients with advanced renal cell carcinoma: Results from a phase III randomized, open-label, multicenter trial.

R. Motzer, A. Berkenblit, C. Sternberg, 2012 .

A phase III, randomized, controlled study to compare tivozanib with sorafenib in patients (pts) with advanced renal cell carcinoma (RCC).

R. Motzer, C. Sternberg, W. Slichenmyer, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Activity of tivozanib (AV-951) in patients with renal cell carcinoma (RCC): Subgroup analysis from a phase II randomized discontinuation trial (RDT).

D. Doval, W. Slichenmyer, R. Chacko, 2010 .

Nuclear Protein of the Testis Midline Carcinoma Masquerading as a Primary Mediastinal Seminoma

M. S. Sayapina, A. Karseladze, D. Nosov, 2016, Rare tumors.

Updated activity and safety results of a phase II randomized discontinuation trial (RDT) of AV-951, a potent and selective VEGFR1, 2, and 3 kinase inhibitor, in patients with renal cell carcinoma (RCC).

R. Chacko, P. Bhargava, O. Lipatov, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Final analysis of the phase II randomized discontinuation trial (RDT) of tivozanib (AV-951) versus placebo in patients with renal cell carcinoma (RCC).

D. Doval, A. Strahs, W. Slichenmyer, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Management of Muscle Invasive Bladder Cancer with Bladder Preservation in Russia: a Survey-Based Analysis of Current Practice and the Impact of an Educational Workshop on Clinical Expertise

Charles R. Thomas, S. Tjulandin, C. Degnin, 2020, Journal of Cancer Education.

Nilotinib versus imatinib as first-line therapy for patients with unresectable or metastatic gastrointestinal stromal tumours (ENESTg1): a randomised phase 3 trial.

J. Blay, G. Demetri, Yoon-Koo Kang, 2015, The Lancet. Oncology.

Tivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma: results from a phase III trial.

R. Motzer, D. Cella, A. Berkenblit, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Antitumor activity and safety of tivozanib (AV-951) in a phase II randomized discontinuation trial in patients with renal cell carcinoma.

D. Doval, A. Strahs, W. Slichenmyer, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial.

T. Powles, M. Atkins, E. Plimack, 2020, The Lancet. Oncology.

Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal‐Cell Carcinoma

T. Powles, M. Atkins, E. Plimack, 2019, The New England journal of medicine.

Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for metastatic renal cell carcinoma (mRCC): Outcomes in the combined IMDC intermediate/poor risk and sarcomatoid subgroups of the phase 3 KEYNOTE-426 study.

T. Powles, M. Atkins, E. Plimack, 2019, Journal of Clinical Oncology.

Localization of point mutations in the coding part of the VHL gene in clear cell renal cancer

V. Matveev, I. Rusakov, D. Zaletaev, 2012, Molecular Biology.

Phase III trial of nilotinib versus imatinib as first-line targeted therapy of advanced gastrointestinal stromal tumors (GIST).

J. Blay, G. Demetri, Yoon-Koo Kang, 2013 .

Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma (ccRCC): Results from 42-month follow-up of KEYNOTE-426.

T. Powles, E. Plimack, B. Melichar, 2021, Journal of Clinical Oncology.

Pembrolizumab plus axitinib versus sunitinib as first-line therapy for advanced renal cell carcinoma (RCC): Updated analysis of KEYNOTE-426.

T. Powles, M. Atkins, E. Plimack, 2020, Journal of Clinical Oncology.

Genitourinary tumors, non-prostate

S. J. Park, I. Tannock, S. Groshen, 2012 .

Overall survival results from a phase III study of tivozanib hydrochloride versus sorafenib in patients with renal cell carcinoma.

A. Berkenblit, A. Strahs, C. Szczylik, 2013, Journal of Clinical Oncology.

O4 Tivozanib hydrochloride versus sorafenib as initial targeted therapy for patients with advanced renal cell carcinoma: Results from the Phase III randomized, open-label, multicenter TIVO-1 trial

R. Motzer, A. Berkenblit, C. Sternberg, 2012 .

Efficacy and safety data from patients with advanced renal cell cancer treated with tivozanib hydrochloride after progression on sorafenib.

A. Berkenblit, A. Strahs, P. Tomczak, 2013, Journal of Clinical Oncology.

Management of Muscle Invasive Bladder Cancer with Bladder Preservation in Russia: a Survey-Based Analysis of Current Practice and the Impact of an Educational Workshop on Clinical Expertise

Charles R. Thomas, S. Tjulandin, C. Degnin, 2019, Journal of Cancer Education.

Clinical outcomes by nephrectomy status in METEOR, a randomized phase 3 trial of cabozantinib (cabo) vs everolimus (eve) in patients (pts) with advanced renal cell carcinoma (RCC).

R. Motzer, T. Powles, T. Choueiri, 2017 .

Outcomes for patients in the pembrolizumab+axitinib arm with advanced renal cell carcinoma (RCC) who completed two years of treatment in the phase III KEYNOTE-426 study.

T. Powles, M. Atkins, E. Plimack, 2021 .

Activity of tivozanib (AV-951) in patients (Pts) with different histologic subtypes of renal cell carcinoma (RCC).

D. Doval, W. Slichenmyer, R. Chacko, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Factors affecting the efficacy of gemcitabine and nab-paclitaxel (paclitaxel + albumin) combination in the Russian patient population: results of a multicenter retrospective study

F. Moiseenko, O. Kit, D. Nosov, 2019, Medical Council.

Pembrolizumab plus axitinib versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma: 5-year analysis of KEYNOTE-426.

E. Plimack, B. Melichar, B. Rini, 2023, Journal of Clinical Oncology.

Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for locally advanced or metastatic renal cell carcinoma (mRCC): phase III KEYNOTE-426 study.

T. Powles, M. Atkins, E. Plimack, 2019, Journal of Clinical Oncology.

Clinical Outcomes by Nephrectomy Status In METEOR, A Randomized Phase 3 Trial of Cabozantinib Versus Everolimus in Patients with Advanced Renal Cell Carcinoma

T. Powles, R. Motzer, T. Choueiri, 2020, Kidney Cancer.

Pembrolizumab Plus Axitinib Versus Sunitinib as First-line Treatment of Advanced Renal Cell Carcinoma: 43-month Follow-up of the Phase 3 KEYNOTE-426 Study.

M. Atkins, E. Plimack, B. Melichar, 2023, European urology.

Tivozanib versus sorafenib as initial targeted therapy for patients with advanced renal cell carcinoma: Results from a phase III randomized, open-label, multicenter trial.

R. Motzer, A. Berkenblit, C. Sternberg, 2012 .